ASCO 2018

Viewing 1-20 of 140 articles

ASCO 2018: Relapse-Free Survival of Clinical T2-4N0 Urothelial Bladder Carcinoma After Radical Cystectomy, with or without Perioperative Chemotherapy: Endpoints for Clinical Trial Design.

ASCO 2018: Treatment of mHSPC and Implications for Subsequent Management

ASCO 2018: Measurable Immunologic Changes and Improved Clinical Activity in mRCC with Nivolumab + Bevacizumab or Nivolumab + Ipilimumab

ASCO 2018: Pembrolizumab plus Enzalutamide in mCRPC: Extended Follow Up

ASCO 2018: Enzalutamide Plus CC-115 in Men with mCRPC: A Phase 1b Prostate Cancer Clinical Trials Consortium Study

ASCO 2018: Perspective on Balancing Toxicities in the Treatment of mHSPC

ASCO 2018: Long-Term Androgen Deprivation, With or Without Radiotherapy, in Locally-Advanced Prostate Cancer: Updated Results from a Phase III Randomized Trial

ASCO 2018: Optimal Patient Selection/Stratification Perspective

ASCO 2018: Ten Year Treatment Outcomes of Radical Prostatectomy Vs External Beam Radiation Therapy Vs Brachytherapy for 1,503 Patients With Intermediate Risk Prostate Cancer

ASCO 2018: Optimizing Androgen Receptor Targeting Strategies Perspective

ASCO 2018: Approaches in Management of Refractory Germ Cell Cancer

ASCO 2018: Long-Term Patterns in Race-specific, Distant Metastasis-free Survival Following Radiation Treatment for Prostate Cancer

ASCO 2018: Impact of Treatment Sequence on the Outcomes of Metastatic Castration Resistant Prostate Cancer Patients With Germline BRCA2 Mutations: A Subanalysis of the PROREPAIR-B Study

ASCO 2018: Survivorship and Surveillance in Management of Germ Cell Cancer

ASCO 2018: CABOPRE: Phase II Study of Cabozantinib Prior to Cytoreductive Nephrectomy in Locally Advanced and/or Metastatic Renal Cell Carcinoma

ASCO 2018: State-of-the-Art Management of Germ Cell Cancer

ASCO 2018: PROPHECY - A Prospective Trial of Circulating Tumor Cell AR-V7 Detection in mCRPC with Abiraterone or Enzalutamide

ASCO 2018: NIVES study: A Phase II Trial of Nivolumab Plus Stereotactic Body Radiotherapy in II And III Line of Patients with Metastatic Renal Cell Carcinoma

ASCO 2018: Leveraging Social Media to Advance Cancer Research: Challenges and Opportunities

ASCO 2018: KEYNOTE-199: Pembrolizumab for docetaxel-refractory Metastatic Castration-Resistant Prostate Cancer (mCRPC)

1
2
3
4
5
6
7